Lead Product(s): TG01
Therapeutic Area: Oncology Product Name: TG01
Highest Development Status: IND Enabling Product Type: Vaccine
Partner/Sponsor/Collaborator: IOVaxis Therapeutics
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 06, 2021
Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore.